Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Stargardt Disease
— Second of four products in Phase I/II ocular programme partnered with sanofi-aventis approved to enter clinical development — Oxford, UK –… Read More
Oxford BioMedica Announces Publication of Trovax® Phase III Analyses in Cancer Immunology, Immunotherapy
— Immune Response Surrogate Algorithm Shown to be a Significant Predictor of Clinical Benefit — Oxford, UK – 15 March 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)… Read More
Oxford BioMedica Plc Preliminary Results for the Year Ended 31 December 2010
Click here to download the full 2010 preliminary results statement.Click here to download the 2010 results slide deck.Click… Read More
Oxford BioMedica Appoints James Christie as New Head of Manufacturing
Oxford, UK – 9 February 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy company, today announces the appointment of James Christie, BSc, MBA to the newly created role of Head of… Read More
Oxford BioMedica Acquires GMP Manufacturing Facility
— Support for Oxford BioMedica’s five LentiVector® technology-based programmes — — UK production facility in Oxford to… Read More
Results Of Firm Placing And Placing And Open Offer
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION… Read More